Discussing Efficacy & Safety Data for CD47-Targeting Therapy

Time: 12:00 pm
day: Day Two


• Sharing patient outcomes, toxicology studies, and dose escalation rationale

• Considering the safety concerns of a ubiquitously expressed target such as CD47, and the toxicity seen in the clinic

• Translating CD47 therapies to show targeting and validation of targets